Skip to content

Study · Non-randomized trial · n = 8 · 1984

2 results

Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans.

Ehrensing RH, Kastin AJ, Michell GF

Pharmacology, biochemistry, and behavior1 Dec 1984Cited by 29 (Europe PMC)

PMID6151672 (opens in a new tab)DOI10.1016/s0091-3057(84)80083-0 (opens in a new tab)PepBankPUB-06151672
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In men given morphine, MIF‑1 increased immersion-phase pain scores versus placebo at 45 and 75 minutes after morphine.

    In plain wordsIn men given morphine, MIF‑1 increased pain during cold-water immersion versus placebo at 45 and 75 minutes.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseCold pressor pain during immersion
    Study

    n = 8

    Comparator
    Placebo followed by morphine
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    60 mg · oralAs given in this study (human).

    Source sentences

    Summary
    Analysis of variance revealed that MIF-1 resulted in significantly higher scores (less analgesia) compared with placebo when measured at 45 and 75 min after morphine during the immersion phase and during all four times the subjects were evaluated during the removal phase.
    1 context sentence
    Summary · context
    Eight men received a capsule containing 60 mg of MIF-1 or placebo followed one hour later by a 10 mg intramuscular injection of morphine in a double-blind, crossover design at two visits 4 weeks apart.
  2. 02HumanNon-randomized trialEfficacy outcome

    In men given morphine, MIF‑1 increased removal-phase pain scores versus placebo at all four assessment times.

    In plain wordsIn men given morphine, MIF‑1 increased pain after foot removal versus placebo at all four assessment times.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseCold pressor pain after foot removal
    Study

    n = 8

    Comparator
    Placebo followed by morphine
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    60 mg · oralAs given in this study (human).

    Source sentences

    Summary
    Analysis of variance revealed that MIF-1 resulted in significantly higher scores (less analgesia) compared with placebo when measured at 45 and 75 min after morphine during the immersion phase and during all four times the subjects were evaluated during the removal phase.
    2 context sentences
    Summary · context
    Experimental pain was induced by the cold pressor test administered 45, 75, 120 and 180 min after the morphine.
    Summary · context
    Eight men received a capsule containing 60 mg of MIF-1 or placebo followed one hour later by a 10 mg intramuscular injection of morphine in a double-blind, crossover design at two visits 4 weeks apart.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.